TETRA BIO-PHARMA INC Stock News

Tetra Bio-Pharma Inc (TSE:TBP) (OTCMKTS:TBPMF) (FRA:JAM1) has struck a definitive deal with Danish biopharma DanCann Pharma for the distribution of three of its products in the Nordics and Germany, wh

This Definitive Agreement is expected to generate an excess of $ 47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQ

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) has announced it will reactivate a clinical trial to evaluate the safety, tolerability, and potential efficacy of its veterinary ophthalmic drug

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, revealed that it has been granted a Health Canada Drug Establishment License (D

The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, has submitted a request to the Malta Medicines Authority for a Scientific Opini

Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabi

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it has shipped its investigational new drug, QIXLEEF, to the US to initiate the planned REBORN1 study of patients with breakthrough cancer

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) revealed that it has been granted a new patent from the United States Patent and Trademark Office for its method of treating interstitial cysti

Tetra strengthens its intellectual property portfolio Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. ("Tet

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) revealed that it has advanced its REDUVO cannabinoid soft gel capsules New Drug Submission (NDS) file by responding to a request for more inform

REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced Monday that the US Food and Drug Administration (FDA) had positive things to say during a review of the preclinical data package and c

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS OTTAW

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced Thursday that the company received a notice of compliance for its Drug Establishment License (DEL) following an audit by the Drug GMP